AstraZeneca/Bristol's Onglyza Gains Approval, But Now Has To Face Januvia

Gaining FDA approval was only the first hurdle for AstraZeneca and Bristol-Myers Squibb's dipeptidyl peptidase-4 inhibitor Onglyza. A potentially even bigger challenge now lies ahead: positioning the drug against Merck's first-in-class blockbuster Januvia